Evidence map›Paper›PMID 39872051›Full record

ArticleFrontiers in pharmacology2024

Ultrasound-guided thoracic paravertebral injection of dexamethasone palmitate combined with ropivacaine for the treatment of thoracic herpes zoster-related pain: protocol for a prospective, randomized controlled, single-center study.

Liu Wang, Shengrong Xu, Zongbin Jiang, Ruilin He

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liu Wang *Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Shengrong Xu *Department of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Zongbin JiangDepartment of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Ruilin HeDepartment of Pain Medicine, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Herpes zoster (HZ) patients often experience herpes zoster-associated pain (ZAP). Thoracic paravertebral nerve block has been proven effective in relieving ZAP and reducing the incidence of postherpetic neuralgia (PHN). Compared to dexamethasone, dexamethasone palmitate (DXP) has stronger anti-inflammatory effects, a longer duration of action, and fewer adverse reactions. This study evaluates the efficacy and safety of ultrasound-guided thoracic paravertebral injection of DXP combined with ropivacaine for treating thoracic ZAP, compared to traditional famciclovir therapy. Methods: This prospective, randomized, controlled, open-label, endpoint-blinded, single-center trial will recruit 254 patients with ZAP. Patients will be randomly assigned in a 1:1 ratio to the intervention group (thoracic paravertebral injections of DXP combined with ropivacaine and antiviral therapy) or the control group (antiviral therapy). Assessments will include pain intensity, quality of life, sleep quality, inflammatory markers, and adverse events. Ethics and registration: This study strictly adheres to the 2013 SPIRIT Statement and the Declaration of Helsinki and has been approved by the Ethics Committee of the Second Affiliated Hospital of Guangxi Medical University (Approval Number: 2024-KY(0505)). This clinical trial is registered on the Chinese Clinical Trial Registry platform (ChiCTR) at https://www.chictr.org.cn/index.html (ChiCTR2400087273), registered on 2024-07-24. The results will be disseminated through scientific journals and conferences, aiming to provide evidence supporting the global management of ZAP. The study is expected to start on 1 August 2024, and continue until 31 July 2027.

Indexed as

dexamethasone palmitateherpes zoster painpain managementparavertebral injectionropivacaine

Identifiers

PMID39872051
PMCPMC11770281

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.